To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension. Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,001
Unnamed facility
Sapporo, Hokkaido, Japan
Change from baseline in sitting blood pressure
Change from baseline in sitting systolic (SBP) and diastolic blood pressure (DBP).
Time frame: Baseline to end of Week 12
Change from baseline in 24 hour average blood pressure
Change from baseline in 24 hour average systolic and diastolic blood pressure.
Time frame: Baseline to end of Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.